Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases

Czech version

Authors: Ondřej Viklický ¹; Romana Ryšavá ²; Vladimír Tesař ²; Ivan Rychlík ³; Martin Prázný ⁴; Richard Češka ⁴; Martin Haluzík ⁵
Authors‘ workplace: Klinika nefrologie, Transplantační centrum, IKEM, Praha ¹; Klinika nefrologie, VFN a 1. LF UK, Praha ²; Interní klinika FNKV a 3. LF UK, Praha ³; III. interní klinika VFN a 1. LF UK, Praha ⁴; Centrum diabetologie, IKEM, Praha ⁵
Published in: Vnitř Lék 2022; 68(7): 426-431
Category: Main Topic
doi: https://doi.org/10.36290/vnl.2022.090

Overview

Chronic kidney disease (CKD) affects 10% of the population of developed countries and significantly affects the population health. In addition to the well-known renoprotection tools slowing down the progression of CKD, SGLT2 inhibitors have been newly introduced into clinical practice based on the results of extensive studies, both in diabetics and non-diabetics. This expert opinion discusses the classification of CKD, current renoprotection options, and the recent role of SGLT2 inhibitors in the care of patients with CKD.

Keywords:

SGLT2 inhibitors – gliflozins – chronic kidney disease – CKD progression – renoprotection

Sources

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2013;Suppl 3:1-150.

2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O‘Callaghan CA, Lasserson DS, Hobbs FD. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta‑Analysis. PLoS One. 2016 Jul 6;11(7):e0158765.

3. Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J, Kastarinen M, Guessous I, Vinhas J, Stengel B, Brenner H, Chudek J, Romundstad S, Tomson C, Gonzalez AO, Bello AK, Ferrieres J, Palmieri L, Browne G, Capuano V, Van Biesen W, Zoccali C, Gansevoort R, Navis G, Rothenbacher D, Ferraro PM, Nitsch D, Wanner C, Jager KJ; European CKD Burden Consortium. CKD Prevalence Varies across the European General Population. J Am Soc Nephrol. 2016 Jul;27(7):2135-47.

4. Zima T, Racek J, Tesař V, Viklický O, Teplan V, Schück O, Janda J, Friedecký B, Kubíček Z, Kratochvíla J, Rajdl D, Šálek T, Kalousová M and Granátová J. Doporučení České nefrologické společnosti a České společnosti klinické biochemie ČLS JEP 2014. Doporučení k diagnostice chronického onemocnění ledvin (odhad glomerulární filtrace a vyšetřování proteinurie) http://www.nefrol.cz/odbornici/doporucene‑postupy‑cns. 2014.

5. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end‑stage kidney disease. Cochrane Database Syst Rev. 2014 Jun 18;(6):CD007333. doi: 10.1002/14651858.CD007333.pub2. PMID: 24938824.

6. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, Knoll GA, Muntner P, Pecoits‑Filho R, Sarnak MJ, Tobe SW, Tomson CRV, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli M, Cheung M, Earley A, Mann JFE. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3):559-569.

7. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G and Investigators F‑D. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219-2229.

8. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B and Investigators E‑RO. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375:323-34.

9. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657.

10. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause‑Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS and Investigators D‑T. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347-357.

11. Heerspink HJL, Stefánsson BV, Correa‑Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA‑CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446.

12. Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits‑Filho R, Correa‑Rotter R, Rossing P, Sjöström CD, Umanath K, Langkilde AM, Heerspink HJL; DAPA‑CKD Trial Committees and Investigators. A pre‑specified analysis of the DAPA‑CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021 Jul;100(1):215-224.

13. Jongs N, Chertow GM, Greene T, McMurray JJV, Langkilde AM, Correa‑Rotter R, Kashihara N, Rossing P, Sjöström CD, Stefánsson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA‑CKD Trial Committees and Investigators. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. J Am Soc Nephrol. 2022 Aug 17:ASN.2022030306. doi: 10.1681/ASN.2022030306.

14. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O‘Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM, Committees D‑HT and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008.

15. KDIGO 2013 (KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease, Kidney Int Suppl 2013;3(3).

16. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner‑La Rocca HP, Choi DJ, Chopra V, Chuquiure‑Valenzuela E, Giannetti N, Gomez‑Mesa JE, Janssens S, Januzzi JL, Gonzalez‑Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR‑Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461.

17. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS; Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C‑Based Equations to Estimate GFR without Race. N Engl J Med. 2021 Nov 4;385(19):1737-1749.

18. Rychlík I, Francová L. Statistická ročenka dialyzační léčby v České republice v r. 2021. Česká nefrologická společnost 2022. https://www.nefrol.cz/odbornici/dialyzacni‑statistika